Microbix partners with Angiogen for urokinase cancer treatment
Microbix Biosystems Inc. is partnering with Angiogen LLC to commercialize a novel technology for the treatment of solid cancers by exclusively providing the urokinase needed for Angiogen's patented drug therapy. According to the company, Microbix made a large investment this year in its product pipeline starting with the acquisition of a new production site in Toronto with the capacity to produce commercial quantities of urokinase.
"Having this facility and the urokinase technology allowed us to establish an exclusive relationship with Angiogen, the company that has a patented use of urokinase as they pursue indications in the treatment of cancers such as colorectal and prostate," said William J. Gastle, President and CEO of Microbix.
Financial activities required to complete Phase 1 and Phase 2 clinical trials are expected to conclude in 2007 after which the companies expect to complete the Phase 1 trial in 2008.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.